WallStreetZenWallStreetZen

NASDAQ: AKTX
Akari Therapeutics PLC Stock Ownership - Who owns Akari Therapeutics?

Insider buying vs selling

Have Akari Therapeutics PLC insiders been buying or selling?
Buy
Sell
NameRoleDateSharesPriceValue
Samir Rashmikant PatelDirector2024-05-311,326,258,000$0.00
$1.33MBuy
Raymond PrudochleboszDirector2024-05-311,326,258,000$0.00
$1.33MBuy

1 of 1

AKTX insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when AKTX insiders and whales buy or sell their stock.

AKTX Shareholders

What type of owners hold Akari Therapeutics PLC stock?
Institutional
Insider
Retail
NameHoldSharesValueType
Raymond Prudochlebosz28.38%4,497,314,800$16.69BInsider
Samir Rashmikant Patel21.53%3,411,495,500$12.66BInsider
Rachelle Suzanne Jacques6.42%1,018,027,792$3.78BInsider
Rpc Pharma Ltd4.56%722,345,600$2.68BInsider
James Hill4.56%722,345,600$2.68BInsider
Ray Prudo4.56%722,345,600$2.68BInsider
Stuart Ungar4.56%722,345,600$2.68BInsider
Wendy F. Dicicco1.00%158,473,915$587.94MInsider
Michael Grissinger0.13%20,000,000$74.20MInsider
Donald A. Williams0.13%20,000,000$74.20MInsider

1 of 3

AKTX vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
AKTX0.00%75.83%Net BuyingNet Buying
CELU0.58%99.42%Net BuyingNet Selling
THTX31.05%0.00%
CALC13.65%86.35%Net BuyingNet Buying
NTRB2.29%51.37%

Akari Therapeutics Stock Ownership FAQ

Who owns Akari Therapeutics?

Akari Therapeutics (NASDAQ: AKTX) is owned by 0.00% institutional shareholders, 75.83% Akari Therapeutics insiders, and 24.17% retail investors. Raymond Prudochlebosz is the largest individual Akari Therapeutics shareholder, owning 4.50B shares representing 28.38% of the company. Raymond Prudochlebosz's Akari Therapeutics shares are currently valued at $16.69B.

If you're new to stock investing, here's how to buy Akari Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.